LY411575 is not unique and one of many compounds developed as potential therapeutic agents for the treatment of Alzheimer's disease (AD) that appear capable of blocking GSI and SPP activity. The gene discussed is HM13; the disease is early-onset autosomal dominant Alzheimer disease.